The Rash That Turns Out to Be a Lymphoma: Mycosis Fungoides
A scaly patch shows up on a hip or a buttock. A steroid cream flattens it, and months later it is back, slightly wider. Another cream, another dermatologist, another year. Almost always that is eczema or psoriasis behaving badly, and the cream is the right answer. Occasionally it is a lymphoma growing in the skin, and the biopsy that finally names it is usually not the first one taken. What gives it away is rarely one slide. It is the shape of the whole record: how long the patches have been there, where they sit, and what three pathologists wrote in three different years. Holding that record as one line instead of three visits is what Healz's memory does.
This post takes mycosis fungoides from the top: why early biopsies come back as dermatitis, what immunohistochemistry and a clonality result settle, how it is staged, and why treatment starts on the skin. It is a rare cancer, and the overwhelming majority of long-running rashes are not it.

Why a rash gets years of creams before anyone says lymphoma
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, a cancer of T lymphocytes that presents in the skin (per the Cutaneous Lymphoma Foundation). Counting its variants, it makes up more than half of all primary cutaneous lymphomas (per Yamashita et al., Anais Brasileiros de Dermatologia, 2012). It is still uncommon: the PROCLIPI investigators put the incidence at under 1 per 100,000, while noting prevalence is far higher than that implies, because people live a long time with early disease (British Journal of Dermatology, 2019).
The reason it hides is that it acts like a rash. NCI describes the natural history as indolent and says symptoms may be present for long periods, in a range of 2 to 10 years, because the eruptions wax and wane before a biopsy confirms them. A patch that flattens under a cream and returns next winter reads as stubborn dermatitis, not as cancer.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The delay has been measured. PROCLIPI, an international registry, confirmed 348 patients with early-stage mycosis fungoides at central review. Of those, 85.6% reported a delay between first symptom and diagnosis, median 36 months, interquartile range 12 to 90 months. The authors name the cause rather than blame anyone: varied clinical appearance, resemblance to inflammatory skin disease, and no single specific diagnostic test.
Where the patches sit, and what patch, plaque and tumour mean
Distribution is one of the oldest clues. Mycosis fungoides can appear anywhere, but it favours skin that clothing keeps out of the sun (per the Cutaneous Lymphoma Foundation). NCI's patient summary describes the earliest phase as a scaly red rash in areas of the body that usually are not exposed to the sun, and that dermatology review puts the early lesions particularly in the gluteal region and the root of the thighs. A years-long rash confined to the swimsuit area is a different story from one on the forearms.
The classic progression is patch, then plaque, then tumour, and not everyone passes through all three. Patches are usually flat and can be smooth or scaly, which is exactly why they read as a rash. Plaques are thicker and raised. Tumours are nodules that may ulcerate (per the Cutaneous Lymphoma Foundation), and because the pace is slow, one person can sit at the patch stage for years. For how other long-standing skin lesions get sorted out, our piece on basal cell versus squamous cell skin cancer covers the commoner pair a changing patch is checked against first.
What the first biopsy can and cannot settle
NCI states that the histologic diagnosis is usually difficult to determine in the initial stages and may require the review of multiple biopsies by an experienced pathologist, and its patient summary says plainly that more than one skin biopsy may be needed. Early on, the picture under the microscope is often non-specific and overlaps with ordinary inflammatory conditions (per the Anais Brasileiros de Dermatologia review), because the features pathologists look for in established disease, a band-like upper dermal infiltrate and Pautrier abscesses in the epidermis (per NCI), are frequently not there yet.
Treatment itself blurs the slide. That review notes topical corticosteroids make the histology less specific and advises roughly 2 to 4 weeks off treatment before a biopsy, with the same caution for phototherapy. The cream prescribed for a presumed eczema can soften the evidence that would have named the lymphoma.
So the diagnosis is built, not read off one report. The PROCLIPI authors note that inter-observer variation in diagnosing T-cell lymphomas is well recognised, with discordance around 20%, and that a definite diagnosis often requires careful clinicopathologic correlation. The International Society for Cutaneous Lymphomas formalised that: its algorithm scores clinical, histopathologic, immunopathologic and molecular features together, requiring four points in total for a diagnosis of early mycosis fungoides (Pimpinelli et al., Journal of the American Academy of Dermatology, 2005). A non-diagnostic biopsy in a rash with the right history and distribution does not end the question, and repeat sampling over time is what that pattern prompts.
What immunohistochemistry and a clonality result actually prove
Two laboratory tests get treated as verdicts and are not. The first is immunophenotyping. The typical mycosis fungoides phenotype is CD2 positive, CD3 positive, CD4 positive, CD5 positive, CD8 negative and CD45RO positive, with CD20 and CD30 negative. Loss of CD7 can appear early, but that review is explicit that isolated negativity for CD7 is not a sufficient criterion for diagnosis.
The second is T-cell receptor clonality, done by polymerase chain reaction or Southern blot analysis of the T-cell receptor gene (per NCI). Two limits matter. Sensitivity is modest early: the Anais Brasileiros de Dermatologia review reports that only 53% of early-stage cases showed a population of monoclonal T-lymphocytes, and the PROCLIPI authors state that clonality alone is not a reliable sensitive diagnostic test. Specificity is imperfect too, because clonal T-cell expansion also turns up in other skin diseases, including persistent inflammatory infiltrates. NCI's summary is the sentence worth keeping: none of these tests is individually pathognomonic for lymphoma. A positive clonality result raises the score. It does not close the case, and a negative one does not clear it.
What the staging measures, and why early and advanced behave differently
Staging uses the familiar T, N and M categories with a fourth letter added: the ISCL and EORTC added B for blood, so the system is TNMB (Olsen et al., Blood, 2007; the categories below are as NCI reproduces them). T runs from patches, papules or plaques over less than 10% of the skin (T1) and 10% or more (T2) to tumours at least 1 cm across (T3) and confluent redness over at least 80% of the body (T4). B0 means 5% or fewer of blood lymphocytes are atypical Sezary cells, and B2 means a high tumour burden in the blood. Those letters assemble into stage groups from IA through IVB.
The split between early and advanced disease is stark. NCI reports a median survival of 20 years or more for stage IA, and notes most deaths in that group are not caused by or related to mycosis fungoides. For stage III through stage IV, more than 50% of patients die of the disease, with a median survival of approximately 5 years. The PROCLIPI authors add that up to a third of people presenting with early-stage disease progress to advanced stage within 10 years, which is why follow-up continues even when the skin looks quiet.
Sezary syndrome is the leukaemic form. NCI describes it as a rare leukemic variant of cutaneous T-cell lymphoma with erythroderma, circulating Sezary cells with cerebriform nuclei, lymphadenopathy and itching, requiring a circulating T-cell clone plus Sezary cells of at least 1,000 per microlitre, and gives a median survival of 4 years. The systemic signs checked when any lymphoma is suspected are covered in our piece on the B symptoms of lymphoma.
Why treatment starts on the skin, not in a vein
Early mycosis fungoides is not treated like an aggressive lymphoma, because it is not one. The EORTC consensus recommendations for the treatment of mycosis fungoides and Sezary syndrome, update 2023 (European Journal of Cancer), state that skin-directed therapies remain the preferred approach for early-stage disease, and that most patients with early-stage disease have a normal life expectancy, while morbidity and quality of life can still suffer badly. The options NCI lists for stages I and II are aimed at the skin itself: PUVA, narrowband UVB, topical therapies and total skin electron beam radiation.
For advanced disease the framing changes. NCI states there is no curative therapy and that treatment for most patients is considered palliative, and the EORTC group notes long-term remission is achieved only in a highly selected subset, typically through allogeneic stem cell transplantation.
How Healz reads years of dermatology notes as one case
Years of dermatology notes, photographs of the same patch in different lights, and three biopsy reports from three pathologists are one case. They usually get handled one appointment at a time. Healz is equipped with memory: it pulls the medical facts out of every upload, dates each finding, keeps abnormal values up front, and connects the 2022 biopsy wording to the 2026 one, so the pattern that actually diagnoses mycosis fungoides, which only exists across time, is visible instead of recalled.
The rest sits in that same chat, not across ten apps and four portals. Frontier AI works the case. As a cancer ai that can read pathology report wording, it takes the dermatopathology description, the immunohistochemistry panel and the clonality result together rather than one page at a time. Healz is equipped with root-cause technology, so it does not stop at the first label on the chart: it asks what a rushed visit skips, cross-checks the case against more than a million rare cases, and drills toward the true cause, which is how a presumed eczema that never cleared gets reconsidered rather than re-creamed. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Can mycosis fungoides be misdiagnosed as eczema or psoriasis?
Yes, and it commonly is. Early lesions resemble inflammatory skin disease, the early histology is often non-specific, and no single test settles it. In a registry of 348 confirmed early-stage patients, 85.6% had a delay between first symptom and diagnosis, median 36 months (PROCLIPI, British Journal of Dermatology, 2019).
- How many skin biopsies does it take to diagnose mycosis fungoides?
There is no fixed number. NCI states the histologic diagnosis is usually difficult in the initial stages and may require the review of multiple biopsies by an experienced pathologist, and its patient summary says more than one skin biopsy may be needed. The diagnosis is assembled from clinical, histologic, immunopathologic and molecular features scored together, needing four points on the ISCL algorithm (Pimpinelli et al., JAAD, 2005).
- Does a positive T-cell clonality test mean I have lymphoma?
Not on its own. Clonal T-cell expansion also occurs in other skin diseases, and some studies have found a monoclonal T-cell population in only 53% of early-stage cases (review in Anais Brasileiros de Dermatologia, 2012). NCI puts it directly: none of these tests is individually pathognomonic for lymphoma.
- Is mycosis fungoides curable, and what is the survival rate?
Outlook depends heavily on stage. NCI reports a median survival of 20 years or more for stage IA, with most deaths in that group unrelated to the lymphoma, while more than 50% of patients with stage III through IV disease die of it, median approximately 5 years. For advanced disease NCI states there is no curative therapy and treatment is largely palliative.
A patch treated as eczema for five years is still, almost always, eczema. What separates the rare exception from the rule is not one biopsy but the record around it: where the patches sit, how long they have been there, and what each pathologist actually wrote. That record only exists if someone is holding all of it at once.
Written by Healz Team · Filed under Health Insights